Revenue segments as reported by the company.

Life Sciences and Applied Markets Group

Diagnostics and Genomics Group

Agilent CrossLab Group

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Agilent Technologies

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Agilent Technologies posts strong Q1 earnings, eyes PFAS testing and CRISPR expansion

Agilent Technologies delivered robust Q1 results, raised full-year guidance, and remains confident in its growth drivers. Despite challenges in the genomics market and uncertainties ahead, the company is strategically positioned to capitalize on opportunities and drive continued success.

Agilent reports strong Q2 earnings but revises down second-half forecast

Agilent Technologies delivered strong Q2 results but revised down second-half forecasts due to economic uncertainties. The company remains focused on driving margin expansion, cost efficiencies, and customer service excellence. Challenges from macroeconomic factors and market dynamics are being addressed with a strategic outlook for long-term growth.

Agilent Technologies faces China revenue challenges but eyes growth opportunities

Agilent Technologies faces revenue challenges in China but sees growth opportunities in companion diagnostics and liquid biopsy markets. The company remains confident in its ability to drive earnings growth despite recent setbacks.

Agilent reports mixed Q4 results, eyes steady recovery in 2024

Agilent Technologies reported mixed Q4 results with revenue decline but exceeded EPS guidance. While facing challenges in China and certain segments, the company anticipates slow but steady recovery for FY 2024. Agilent is focusing on cost-saving measures, pricing trends, and investments in growth areas like genomics and environmental solutions.

Agilent reports Q1 revenue decline, eyes global growth opportunities

Agilent Technologies' Q1 performance showed revenue decline but with strengths in certain segments like ACG and consumables. Challenges include revenue declines in DGG and LSAG impacting margins. Opportunities lie in global growth prospects and potential market surprises.

Agilent Technologies faces revenue decline but eyes growth opportunities ahead

Agilent Technologies navigated a challenging market in Q2 2024 with revenue declines across all end markets. The company remains focused on customer-centric strategies, cost optimization, and growth investments while addressing visibility challenges and exploring opportunities in high-growth segments.

Agilent reports Q3 earnings beat, eyes growth through acquisitions

Agilent Technologies delivered a solid performance in Q3 2024, exceeding earnings per share guidance and raising revenue and EPS midpoint guidance.
While facing revenue decline, the company's strategic investments and acquisitions signal a focus on growth and innovation.
Challenges include market dynamics and integration risks, but opportunities exist in leveraging digital initiatives and financial strength for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc., (NYSE: A) is introducing two new products at the 72nd ASMS Conference on Mass Spectrometry and Allied Topics. The Agilent 7010D Triple Quadrupole GC/MS System which targets the food and environmental markets, offers precision and sensitivity in gas chromatography-mass spectrometry. Additionally, the Agilent ExD Cell for use with the 6545XT AdvanceBio LC/Q-TOF system, serves the biopharma market and life science research. These ins.

Agilent Announces Cutting-Edge Advances in GC/MS and LC/Q-TOF Technology at ASMS 2024

Agilent's (A) fiscal second-quarter results reflect weak momentum across all end markets.

Agilent (A) Q2 Earnings Beat Estimates, Revenues Fall Y/Y

Agilent Technologies, Inc. (NYSE:A ) Q2 2024 Results Conference Call May 29, 2024 4:30 PM ET Company Participants Parmeet Ahuja - Investor Relations Padraig McDonnell - President & Chief Executive Officer Bob McMahon - Senior Vice President & Chief Financial Officer Phil Binns - President of Agilent Life Sciences & Applied Markets Group Simon May - President of the Agilent Diagnostics and Genomics Group Angelica Riemann - President of Agilent CrossLab Group Conference Call Participants Matt Sykes - Goldman Sachs Jack Meehan - Nephron Research Patrick Donnelly - Citi Vijay Kumar - Evercore ISI Dan Brennan - TD Cowen Rachel Vatnsdal - JPMorgan Doug Schenkel - Wolfe Research Michael Ryskin - Bank of America Dan Arias - Stifel Josh Waldman - Cleeland Research Catherine Schulte - Baird Paul Knight - KeyBanc Operator Ladies and gentlemen, welcome to the Agilent Technologies Q2 2024 Earnings Call. My name is Regina, and I will be coordinating your call today.

Agilent Technologies, Inc. (A) Q2 2024 Earnings Call Transcript

While the top- and bottom-line numbers for Agilent (A) give a sense of how the business performed in the quarter ended April 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Agilent (A) Reports Q2 Earnings: What Key Metrics Have to Say

Agilent Technologies (A) came out with quarterly earnings of $1.22 per share, beating the Zacks Consensus Estimate of $1.19 per share. This compares to earnings of $1.27 per share a year ago.

Agilent Technologies (A) Surpasses Q2 Earnings Estimates

SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A--Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.57 billion for the second quarter ended April 30, 2024, a decline of 8.4% reported and 7.4% core(1) compared to the second quarter of 2023. Second-quarter GAAP net income was $308 million, or $1.05 per share. This compares with $302 million, or $1.02 per share, in the second quarter of fiscal year 2023. Non-GAAP(2) net income was $356 million, or $1.22 per share during the quarter, compared wi.

Agilent Reports Second-Quarter Fiscal Year 2024 Financial Results

Agilent Technologies' (A) second-quarter fiscal 2024 results are likely to reflect solid momentum across the ACG & DGG segments amid softness in the LSAG segment.

Agilent (A) to Report Q2 Earnings: What's in the Offing?

AGCO

Applied Materials

D.R. Horton

EOG Resources

Imperial Oil

JPMorgan Chase & Co

NextEra Energy

NRG Energy

Owens Corning

PulteGroup

QUALCOMM

Steel Dynamics

Texas Instruments

Advanced Drainage Systems

W. R. Berkley

We explain why selling cash-covered puts and covered calls are relatively safe choices for earning a high income. We will discuss how to formulate a sustainable and repeatable income strategy for Options. In this monthly series, we present how to select the right kind of stocks for options income. We present two lists of 10 stocks with multiple scenarios: PUT options and deep-in-the-money CALL options.

Monthly Options Series: Earn A Potentially Consistent 10% Income (June 2024)

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Hans E. Bishop, president and co-founder of Altos Labs, has stepped down from serving on Agilent's board of directors. Bishop joined Agilent's board in July 2017, after holding a range of leadership positions in the pharmaceutical industry. “Hans' extensive life science industry leadership and insight have been of great value to the board. We are grateful for his contributions over the past seven year.

Agilent Announces Hans E. Bishop Has Stepped Down from Board of Directors

Evaluate the expected performance of Agilent (A) for the quarter ended April 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Agilent (A) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates

New instrument delivers the full power and capability of Agilent GCs in a compact design SANTA CLARA, Calif. , May 23, 2024 /PRNewswire/ -- Agilent Technologies Inc.  (NYSE: A) proudly announces the  8850 Gas Chromatograph (GC) System , a small single-channel GC that combines the legacy of the 6850 GC with the capability and system intelligence of the 8890 GC.

Agilent Unveils the 8850 Gas Chromatograph: A Leap Forward in Analytical Excellence

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc., (NYSE: A) will showcase its latest mass spectrometry innovations at the 72nd ASMS Conference on Mass Spectrometry and Allied Topics, scheduled for June 2 - 6, 2024, in Anaheim, California. A global leader in analytical instruments, Agilent continues to drive performance and accessibility in mass spectrometry. “Agilent will make a significant impact at this year's ASMS Conference, unveiling cutting-edge mass spectrometry solutions.

Agilent at ASMS 2024: Driving Scientific Breakthroughs with Unparalleled Mass Spec Solutions

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that CFO Bob McMahon will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York City on Wednesday, June 5, at 8:30 a.m. EDT. Those interested in listening to the live or recorded session can access it from the Agilent Investor Relations website. The recording will be available for 90 days. About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is a global leader i.

Agilent to Participate in Jefferies Global Healthcare Conference

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced two Solutions Innovation Research Awards (SIRA) presented to Professors Richard Robinson of Cornell University and Xingchen Ye of Indiana University. These separate awards recognize their outstanding contributions to advanced materials research. Electrocatalysis plays a pivotal role in advancing clean energy systems. Enhancing the efficiency of chemical reactions at electrode surfaces can accelerate the tr.

Agilent Presents Solutions Innovation Research Awards to Cornell and Indiana University Researchers

Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.

Earnings Growth & Price Strength Make Agilent Technologies (A) a Stock to Watch

Agilent (A) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Agilent (A) Beat Estimates Again in Its Next Earnings Report?

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will release financial results for the second quarter of fiscal year 2024 after the stock market closes on May 29. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PT. To join the listen-only conference call webcast, click the link on the Events section of Agilent's investor relations website. A recording of the call will also be available on the website for 90 days. About Agilent T.

Agilent to Announce Second-Quarter Fiscal Year 2024 Financial Results May 29

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.

Why Agilent Technologies (A) is a Top Stock for the Long-Term

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE:A) today announced that Padraig McDonnell has assumed the role of Agilent CEO, effective immediately. His appointment is part of the company's CEO transition plan announced Feb. 21. McDonnell is the fourth CEO in Agilent's history and succeeds Mike McMullen, who will serve as an adviser until he retires Oct. 31. “It's an incredible honor to serve as CEO of this great company that impacts the world by advancing the quality of.

Padraig McDonnell Assumes Agilent CEO Role

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) has announced the NovoCyte Opteon Spectral Flow Cytometer, propelling flow cytometry into a new era of and accessibility. This cutting-edge system sets a gold standard for acquiring, analyzing, and reporting flow data across diverse domains—from basic research to drug discovery and therapy development. The NovoCyte Opteon represents a significant leap forward in flow cytometry technology, with configurations ranging from.

Agilent Announces the NovoCyte Opteon, a Cutting-Edge Spectral Flow Cytometry Solution

SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent Technologies, Inc. (NYSE: A) today announced Simon May has been named president of the company's Diagnostics and Genomics Group (DGG). May, previously executive vice president and president of the Life Science Group at Bio-Rad Laboratories, will join Agilent on May 6. “We are excited to welcome Simon May to the Agilent team,” said Padraig McDonnell, COO and CEO-elect. “Simon's deep technical knowledge, his broad range of experience, and his career-l.

Agilent Names Simon May to Lead Diagnostics and Genomics Group

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announces that it is the recipient of two 2023 Sustainability Scientists' Choice awards — Sustainable Supplier of the Year and Sustainable Product of the Year. These awards recognize Agilent as a leader in the area of sustainability. The award for Sustainable Supplier of the Year, recognizes Agilent's demonstrated commitment to environmental responsibility and sustainability. The award acknowledges efforts in minimizing e.

Agilent Receives Scientists' Choice Awards for Sustainability

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that its GenetiSure Dx Postnatal Assay has received European IVDR Class C Certification. This certification demonstrates that the assay meets the higher standards established by IVDR. It ensures the continued availability of this trusted qualitative assay to clinical geneticists and other healthcare professionals throughout the EU. In vitro diagnostic devices, which include pregnancy tests, COVID-19 tests,.

Agilent Receives European IVDR Class C Certification for GenetiSure Dx Postnatal Assay

Agilent (A) plans to showcase its new products for analytical laboratories at Analytica 2024, boosting its overall product portfolio.

Agilent (A) is Set for Analytica 2024 With Advanced Products

PRINCETON, N.J. and SUZHOU, China , April 8, 2024 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, and Agilent Technologies, announce a collaboration to develop a Claudin18.2 (CLDN18.2) companion diagnostic to support TranStar301 global Phase III pivotal trial of Osemitamab (TST001) in combination with Nivolumab and chemotherapy as first-line treatment in patients with CLDN18.2 expressing locally advanced or metastatic gastric or gastroesophageal (G/GEJ) adenocarcinoma.

News for Agilent Technologies Stock (A)